Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Prime Medicine, Inc.NASDAQ: PRME

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow dips below year-ago levels

Q1 FY2026 financing cash flow of $393K fell 93.5% year over year, behind the +227.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 30.1% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.

Context

  • Financing cash flow amounted to 3271.0% of revenue in FY2025, down 3295.4 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -93.5% toward the trailing-twelve-month pace of +227.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$393K-30.1% QoQ
Last fiscal yearDec 2025
$151.51M-22.6% YoY
LTMMar 2026
$145.91M+227.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.5%——
1 year-22.6%——
3-year CAGR-5.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
151.51M USD
Year-over-year change
-22.6%
4-year CAGR
-13.4%

Financing Cash Flow vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's LTM Mar 2026 financing cash flow of $145.91M is the 3rd largest of the 7 companies compared; the peer median is $76.67M.
  • Its year-over-year change of +227.5% is the 2nd highest of 7, against a peer median of +40.5%.
  • Financing cash flow amounts to 3616.9% of revenue for PRME, versus a peer median of 108.3%.
PRME Competitors Peer median
Financing Cash Flow for PRME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRSPCRISPR Therapeutics AGLTM Sep 2026$719.96M +120.5%+122.7%2860.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$165.06M +31.3%-31.7%249.7%
PRMEPrime Medicine, Inc.LTM Mar 2026$145.91M +227.5%-5.8%3616.9%
BEAMBeam Therapeutics Inc.LTM Jun 2026$107.69M -77.5%+62.4%69.0%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$45.65M +8746.7%+378.4%—
EDITEditas Medicine, Inc.LTM Mar 2026$41.91M -23.0%+215.9%108.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$7.05M +49.8%+31.2%62.9%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding PRME) $76.67M+40.5%+92.5%108.3%

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
Deferred Income Tax(624K)(964K)(279K)00
Stock-Based Compensation1.75M6.46M13.91M26.07M29.27M
Change in Working Capital31.18M(35.4M)2.65M31.08M(5.34M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.19M2.46M9.14M(5.26M)996K
Other Working Capital29.99M(37.86M)(6.49M)36.33M(6.34M)
Other Non-Cash Items98.42M17.68M11.79M9.75M9.27M
Operating Cash Flow(34.08M)(131.83M)(165.41M)(122.87M)(162.56M)
Capital Expenditures(4.15M)(16.1M)(8.72M)(7.29M)(4.53M)
Acquisitions (Net)00000
Purchases of Investments(81.98M)(123.34M)(104.95M)(129.45M)(205.41M)
Sales of Investments13M93M132.56M204.2M101.18M
Other Investing Activities(496K)(665K)(170K)1M0
Investing Cash Flow(73.63M)(47.1M)18.71M68.46M(108.76M)
Debt Repayment00000
Common Stock Issued270.36M185.32M655K170.14M139.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.09M)(3.82M)025.74M12M
Financing Cash Flow269.28M181.49M655K195.88M151.51M
Effect of Forex Changes00000
Net Change in Cash161.57M2.57M(146.05M)141.47M(119.82M)
Free Cash Flow(38.23M)(147.92M)(174.14M)(130.16M)(167.1M)

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.